Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
761.410.47%
QQQ
712.000.47%
BTC/USD
77393.251.1223%
DIA
523.630.55%
GLD
399.030.67%
TLT
80.850.09%

Zevra Therapeutics Inc

ZVRANASDAQ
Trade with Public
Trade with Public
$12.06
0.020.17%
At close: Sep 9, 5:00 PM EST
$12.06
0.020.17%
Pre-Market: 4:25 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Zevra Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Zevra Therapeutics (ZVRA).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

3S.Buy
8Buy
Consensus RatingBuy# Analysts11Avg. Consensus PT$24Upside to Avg. PT+94.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 20, 2026HC Wainwright & Co.Brandon FolkesMaintainedBuy$26
Aug 7, 2026GuggenheimEddie HickmanPT CutBuy$24→$23
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $26 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and maintains $26 price target.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $23

Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $24 to $23.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $28

Citizens analyst Jason N. Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform and raises the price target from $25 to $28.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Zevra Therapeutics, Lowers Price Target to $20

Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $29 to $20.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $24

Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $29 to $24.
Benzinga Newsdesk

Ford To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Monday

Wall Street analysts changed outlook on top names. See all rating changes on Benzinga's analyst ratings page for F, RIVN, TSM, ZVRA, ARWR, VZ, HBAN, GM, SAP, and CHTR.
Avi Kapoor

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved